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Abstract
To determine the impact of pathology review on the management of patients with cervical carcinoma, 264 reports of pathology
review from 230 patients referred to Erasmus MC (2010–2012) were studied retrospectively. Discrepancies between pathologic
diagnoses were classified as ‘major’ if they led to changes in treatment, and as ‘minor’ where there was no change. Patient and
tumor characteristics were analyzed to identify the factors influencing these discrepancies. Fifty-eight (25.2%) discrepancies
were identified; 28 (12.2%) were major, these resulted frequently frommissing essential information, or discordant assessment of
tumor invasion. Pathology review prevented under-treatment of 3.5%, over-treatment of 1.3%, treatment for incorrect malig-
nancy of 1.3%, and enabled definitive treatment of 6.1% of patients. This highlights the importance of pathology review for
appropriate management. Major discrepancies were rare (1%) for patients with macroscopic tumor and histologic diagnosis of
squamous cell carcinoma (n = 100). For these patients, yield of pathology review may be limited.
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Introduction
Routine review of pathology slides from referred patients with
gynecologic malignances is a standard practice across tertiary
care centers, including in The Netherlands [1]. Pathology re-
view improves the quality of healthcare and helps avoid diag-
nostic errors and consequent medical litigations [2–4].
However, pathology review also increases the workload of
the pathologist, administrative burden, and health-care costs.
Treatment of the patient can also be delayed by the pathology
review, which may lead to disease-related complications, or
cause distress to the patient [5].
For cervical carcinoma, accurate histologic typing and
staging is crucial to determine the appropriate surgical and
adjuvant treatment. This retrospective study was therefore
conducted to determine the impact of pathology review on
the management of cervical carcinoma and to identify the
factors influencing the discrepancies in pathology review.
This article is part of the Topical Collection on Quality in Pathology
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Material and methods
The ErasmusMCCancer Institute is the tertiary referral center
for gynecological malignancies for South-West Netherlands.
Patients of all ages referred between January 1st, 2010 and
December 31st, 2012, for the treatment of primary cervical
carcinoma, were included.
Patient characteristics and treatment details were obtained
from hospital records. Clinical descriptions of the tumor by
the referring, as well as the reviewing, gynecologist were ab-
stracted from case notes. Tumors described as having a ‘ma-
lignant appearance’ on inspection by the referral gynecologist
were categorized as macroscopic. Tumors with any other de-
scriptions, e.g., impression of cervical intraepithelial neoplasia
(CIN) or atypical blood vessel pattern on colposcopy, were
classified as non-visible.
Pathology slides from all included patients had been
reviewed by an experienced gynecologic pathologist, occa-
sionally in consultation with a second gynecologic patholo-
gist. For this study, data were extracted from both the original
and the review pathology reports. The extracted data included
the type of specimen and tumor characteristics: size, site of
origin, histologic type, depth of invasion, horizontal
extension, margin status, presence of lymphovascular space
involvement (LVSI), and differentiation grade. Tumor stage
before and after the pathology review was assigned on the
basis of reports using the TNM-Classification. The final tumor
stage was determined by taking into consideration the radiol-
ogy reports, through discussions at the Multidisciplinary
Tumor-Board meetings.
All discordant histologic parameters in the original and
review pathology reports were recorded, and thereafter inde-
pendently reviewed by two gynecologic oncologists (HvB
and HvD). In case of disagreement, consensus was reached
through discussion, and consultation of a third gynecologic
oncologist. If parameter(s) essential for treatment planning
were missing in the original pathology report, e.g., depth of
invasion in a stage T1a carcinoma, this was recorded as miss-
ing essential information.
Reports were not considered to be discrepant if the
original and review diagnoses were essentially in agree-
ment, with or without slight differences in diagnostic ter-
minology, e.g., severe dysplasia and CINIII. Differences
in tumor differentiation grade were also not considered as
discrepancies, as this has no well-defined diagnostic
criteria.
Fig. 1 Flowchart of all patients referred with primary cervical carcinoma to Erasmus MC Cancer Institute from 2010 till 2012
Virchows Arch
Discrepancies in parameters, e.g., LVSI-status, or tumor
stage, which did not alter the treatment, were categorized as
minor, and discrepancies which altered the treatment, e.g.,
change in tumor site or histologic type, were categorized as
major.
For cases with a major discrepancy, the treatment that the
patient would have received based on the original diagnosis
was categorized as under-treatment, over-treatment, treatment
for incorrect malignancy, and no definitive treatment, as de-
scribed below.
Under-treatment: Treatment for carcinoma of a lower
stage.
Over-treatment: Treatment for carcinoma of a higher stage.
Treatment for incorrect malignancy: Treatment for carcino-
ma of a different anatomic site or histologic type.
No definitive treatment: Treatment plan could not be
formulated.
To identify the factors influencing the discrepancies, char-
acteristics of the discrepant cases were compared, which in-
cluded specimen type, presence of macroscopic tumor, inva-
sive-status, and histologic type of tumor (as reported by the
referring pathologist).
Data were analyzed using SPSS version 20.0 (IBM SPSS
Statistics, Chicago, IL). Chi-squared tests or Fisher’s exact
tests were used to identify any significant differences;
p < 0.05 was considered significant. Mantel-Haenszel test
was used to analyze any systematic pattern in discrepancies.
Results
Of 266 referred patients, 36 were excluded as they had no
pathology review (Fig. 1). From the 230 included patients,
there were 264 pathology specimens. These included biopsies
(57.8%), loop electrosurgical excision procedure (LEEP)
specimens (25.7%), cone biopsies (9.1%), total hysterecto-
mies (3.5%), endocervical curettage (3%), and endometrial
curettage (0.9%).
For nine patients, the diagnosis of cervical carcinoma was
ruled out based on clinical features, or pathology review. The
diagnosed carcinomas (n = 221) included squamous cell car-
cinoma (SCC) (70.9%), adenocarcinoma (24.8%), neuroendo-
crine carcinoma (2.6%), adenosquamous carcinoma (0.9%),
and undifferentiated carcinoma (0.9%) (Table 1). Two patients
had both SCC and adenocarcinoma. For both, the diagnosis of
Table 1 Patient characteristics (n = 230)
Characteristics Value
Age in years (± 95% confidence interval) 51.0 (± 15.0)
Type of specimen n (%)
Biopsy 133 (57.8)
LEEP-specimen 59 (25.7)
Cone biopsy 21 (9.1)
Hysterectomy 8 (3.5)
Endocervical curettage 7 (3.0)
Endometrial curettage 2 (0.9)
Further sampling needed n (%) 36 (15.7)
Macroscopic tumor n (%)
Yes 135 (58.7%)
No 95 (41.3%)
Invasive-status n (%)
Invasive 215 (93.5%)
Inconclusive 15 (6.5%)
TNM-staging n = 221a,b n (%)
Tx 5 (2.2%)
Premalignant 2 (0.9%)
T1a1 15 (6.5%)
T1a2 5 (2.2%)
T1b1 88 (38.3%)
T1b2 11 (4.8%)
T2a1 7 (3.0%)
T2a2 1 (0.4%)
T2b 65 (28.3%)
T3a 5 (2.2%)
T3b 10 (4.3%)
T4 7 (3.0%)
Histological type n = 221bn (%)
Squamous cell carcinoma 163 (70.9%)
Adenocarcinoma 57 (24.8%)
Neuroendocrine tumor 6 (2.6%)
Adenosquamous 2 (0.9%)
Undifferentiated 2 (0.9%)
a In nine patients, there was no cervical carcinoma, but endometrial cancer
(n = 6), colon carcinoma (n = 1), ovarian cancer (n = 1), or vaginal cancer
(n = 1)
bDefinitive stage or histologic type
LEEP loop electrosurgical excision procedure
Table 2 Classification of discrepancies
Discrepant parameters Major (n = 28)a Minor (n = 30)b
Missing essential information 10 7
Invasive-status 7 6
Site of origin of tumor 3 2
Histologic type 3 11
LVSI-status 4 2
Tumor size 7 6
Tumor margin status 2 2
LVSI lymphovascular space invasion
a In eight patients, there was more than one major discrepancy
b In six patients, there was more than one minor discrepancy
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SCC was decisive for further treatment planning and was
therefore used for the analysis.
Fifty-eight (25.2%) discrepancies were identified; 28
(12.2%) were major, and 30 (13%) were minor.
Discrepancies arose from missing essential information, or
discordant assessment of histologic parameters, i.e., inva-
sive-status, site of tumor, histologic type, LVSI-status, tumor
size, and margin status (Table 2). More than one factor was
operative in eight cases of major, and six cases of minor dis-
crepancies. Missing essential information caused 27.8% of
major and 19.4% of minor discrepancies. For cases with mi-
nor discrepancies, these items were horizontal extension and
margin status of the tumor. For cases with major discrepan-
cies, these were depth of invasion, horizontal extension, and
LVSI status. Changes in histologic type of tumor caused
30.5% of minor discrepancies.
Pathology review prevented under-treatment of eight pa-
tients (3.5%) and over-treatment of three patients (1.3%).
For three patients (1.3%), treatment for incorrect malignancy
could be avoided, and for 14 (6.1%) patients, definitive treat-
ment plan could be formulated. Following the pathology re-
view, chemo-radiotherapy was canceled for two patients, and
additional cone biopsy was omitted for nine patients. For five
patients, invasive carcinoma was discovered on pathology re-
view, while for two patients, the diagnosis of invasive carci-
noma was changed to carcinoma in situ (Table 3).
On comparing the characteristics of discrepant cases
through Chi-squared test, major discrepancies were found to
be significantly less frequent for patients with macroscopic
tumor and histologic diagnosis of conventional SCC.
However, on stratified Mantel-Haenszel analysis, macroscop-
ic tumor was found to be a confounder, and only histologic
diagnosis of SCC retained statistical significance (p = 0.001).
For patients with a macroscopic tumor and histologic diagno-
sis of conventional SCC (n = 100), only one major discrepan-
cy was found (1.0%, 95% CI 0.0–3.0%). No other factors
significantly influenced the chances of a discrepancy
(Supplementary Table 1).
Discussion
Major discrepancies were identified on pathology review for
12.2% of our cases. Major discrepancy rates varying between
0.6 and 13.5% have been previously reported for gynecologic
oncology [2, 5–12]. Missing essential information, such as
horizontal extension, depth of invasion, and LVSI status, was
the most common cause of major discrepancies. We therefore
recommend implementing synoptic templates, which ensures
standardization of pathology reporting, and usage of uniform
terminology [13–16]. Khalifa et al. hypothesized that incom-
plete reporting results from the lack of awareness of the pe-
ripheral pathologist of the clinical relevance of the prognosticTa
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and predictive parameters [2]. Workgroup meetings at tertiary
centers and discussion of the discrepant cases with the referring
pathologist can prove beneficial in this context.
Discordant assessment of invasive-status and size of the
tumor also led to major discrepancies. Proper presentation of
cone biopsies in separate, well-labeled containers, pinned up
to improve orientation, can facilitate assessment for both re-
ferring and reviewing pathologists [17]. For complicated di-
agnoses, we recommend requesting additional consultation(s).
Pathology review prevented under-treatment of 3.5%,
over-treatment of 1.3%, treatment for incorrect malignancy
of 1.3%, and enabled definitive treatment of 6.1% of patients.
This conclusively elicits the importance of pathology review
at tertiary centers for ensuring appropriate management of
cervical carcinoma.
Significantly fewer major discrepancies were noted in pa-
tients with macroscopic tumors, as was also reported by Chan
et al. [7]. On stratified analysis, histologic diagnosis of SCC
was identified as the only factor significantly associated with
fewer major discrepancies. We noted only one major discrep-
ancy for cases with macroscopic tumor and histologic diagno-
sis of SCC (n = 100). Therefore, for patients with macroscopic
tumor and histologic diagnosis of SCC, yield of pathology
review appears limited. In health-care settings with limited
resources, to reduce the workload and expenditure, omitting
mandatory pathology review for these patients may be con-
sidered. Eskander et al. reported higher rates of discrepancies
for biopsy specimens [5]. This was, however, not reflected in
our study, which might be due to the small sizes of our sub-
groups, or because LEEP/cone biopsies are more frequently
performed for non-visible tumors.
Minor discrepancies were noted in 13% of our cohort.
Similarly to Minig et al., the majority of these arose from
discordant assessment of histologic type [12].
This study suffers from the limitation characteristic of ret-
rospective chart review, such as unrecorded information and
inconsistent quality of information. Since this is a single-
center study, our results may not be generalizable. The pathol-
ogy review was not blinded, and thus, some bias cannot be
ruled out. Moreover, blinded studies have demonstrated that
the reviewed diagnoses may not necessarily be correct [7, 15,
18]. Nevertheless, the findings from a relatively large cohort
are presented, who were treated within a short time span,
during which the diagnosis or treatment did not change.
Conclusion
Pathology review reveals discrepancies of relevance for the
management of cervical carcinoma. For patients with a mac-
roscopic tumor, and pathologic diagnosis of SCC, yield of
mandatory pathology review may be limited, as this rarely
leads to treatment modification.
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